This lifetime economic analysis demonstrates vagal nerve blocking therapy to be a cost-effective alternative to conventional therapy in class 2 and 3 obesity patients.
Robert I. Griffiths, ScD, MS
Advertisement
Articles by Robert I. Griffiths, ScD, MS
Advertisement
Latest Updated Articles
- Cost-Effectiveness Analysis of Vagal Nerve Blocking for Morbid Obesity
Published: August 25th 2017 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis
2
Pulling Back Funding for Research COuld Leave HIV Treatment in Worse State: Patrick Sullivan, DVM, PhD
3
Value-Based Care Interventions and Management of CKD Progression
4
HMA Combination Therapy Boosts Survival in Accelerated- or Blast-Phase MPNs
5
